Aspirin and Clopidogrel Resistance Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

82 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Resistance to antiplatelet drugs (aspirin, clopidogrel) is a recognized phenomenon with a prevalence from 17% to 35%. Resistance as detected by in vitro tests such as Multiple Electrode Aggregometry (MEA) has been shown to predict clinical therapy failure. Resistance can be caused by clinical, cellular and pharmacogenetic factors. Non compliance is suspected to be an important contributing factor. In this study, compliance will be assured with an electronical compliance monitoring system. Factors to non response will be identified to find plausible explanations when in vitro platelet aggregation inhibition is insufficient despite assured compliance. This study will help to disclose the relationship between compliance, biomarker and clinical outcome as well as to quantify the impact of non compliance to the resistance phenomenon as measured by MEA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990

Peripheral Arterial Disease Clopidogrel, Poor Metabolism of

COMPLETED

ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures

NCT00593762

Peripheral Arterial Occlusive Disease

SUSPENDED

Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.

NCT00222261

Coronary Heart Disease Angina Pectoris Atherosclerosis

COMPLETED PHASE4

Antiplatelet Drug Resistances and Ischemic Events

NCT00501423

Symptomatic Atherothrombosis

COMPLETED

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975

Stroke Myocardial Infarctions

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dual therapy (ASS/CLO)

patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel

No interventions assigned to this group

clopidogrel users (CLO)

patients with a prescription for clopidogrel

No interventions assigned to this group

aspirin users (ASP)

patients with a prescription for aspirin

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients prescribed aspirin and/or clopidogrel for both including both cardiovascular and cerebrovascular indications seeing their general practitioner in or nearby Olten/SO for any medical purpose
* Patients with oral and written German language ability

Exclusion Criteria

* Patients living in care homes
* Patients not preparing their drugs on their own (e.g. outpatient medical assistance through "spitex").
* Patients with acute cardiac symptoms

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No